Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?
作者信息
Lee Eudocia Quant, McFaline-Figueroa J Ricardo, Cloughesy Timothy F, Wen Patrick Y
机构信息
Center for Neuro-Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts.
Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
出版信息
Neuro Oncol. 2018 Jul 5;20(8):1144. doi: 10.1093/neuonc/noy092.
Abstract
摘要
相似文献
1
Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas?是时候重新考虑伊立替康在高级别胶质瘤治疗中的作用了吗？
Neuro Oncol. 2018 Jul 5;20(8):1144. doi: 10.1093/neuonc/noy092.
2
Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system.采用临床经颅 MRI 引导聚焦超声系统破坏血脑屏障并在大鼠模型中递送伊立替康。
Sci Rep. 2020 May 29;10(1):8766. doi: 10.1038/s41598-020-65617-6.
3
Lower-grade gliomas: the wrong target for bevacizumab.低级别胶质瘤：贝伐单抗的错误靶点。
Neuro Oncol. 2018 Nov 12;20(12):1559-1560. doi: 10.1093/neuonc/noy165.
4
Designing new drugs for high grade gliomas.
Curr Pharm Des. 2011;17(23):2368-9. doi: 10.2174/138161211797249215.
5
Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.脂质体伊立替康在转移病灶中蓄积，穿过血脑屏障（BTB），并延长三阴性乳腺癌脑转移实验模型中的生存时间。
Pharm Res. 2018 Jan 9;35(2):31. doi: 10.1007/s11095-017-2278-0.
6
Chemotherapy for low-grade gliomas: lessons and questions.低级别胶质瘤的化疗：经验与问题
Oncology (Williston Park). 2014 Dec;28(12):1043-4, 1051.
7
PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity.低级别胶质瘤中的红细胞压积：在不断演变的疾病实体中受益于旧药物。
Neuro Oncol. 2016 Jun;18(6):755-6. doi: 10.1093/neuonc/now098.
8
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.烷化剂增强伊立替康（CPT - 11）对中枢神经系统肿瘤异种移植瘤的活性。
Cancer Chemother Pharmacol. 1998;41(6):485-90. doi: 10.1007/s002800050771.
9
Tailoring chemotherapy for low-grade gliomas.为低级别胶质瘤量身定制化疗方案。
Oncology (Williston Park). 2014 Dec;28(12):1052, 1071.
10
Outcome assessment in gliomas - the way forward.神经胶质瘤的疗效评估——未来之路
Neurol India. 2017 Nov-Dec;65(6):1302-1303. doi: 10.4103/0028-3886.217990.
引用本文的文献
1
Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF-β signaling.辛伐他汀与伊立替康联合化疗对胶质母细胞瘤的协同作用集中于转化生长因子-β信号通路。
J Neurooncol. 2025 May 28. doi: 10.1007/s11060-025-05089-8.
2
Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.端粒维持的机制及恶性脑胶质瘤相关的治疗弱点。
Neuro Oncol. 2024 Jun 3;26(6):1012-1024. doi: 10.1093/neuonc/noae016.
3
Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents.酪氨酰-DNA磷酸二酯酶1和拓扑异构酶I活性作为胶质母细胞瘤对基因毒性剂敏感性的预测指标
Cancers (Basel). 2019 Sep 23;11(10):1416. doi: 10.3390/cancers11101416.
本文引用的文献
1
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.贝伐单抗单药及联合伊立替康治疗复发性胶质母细胞瘤。
J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. Epub 2009 Aug 31.
2
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.复发性胶质母细胞瘤中，先使用单药贝伐单抗，肿瘤进展时再使用贝伐单抗联合伊立替康的II期试验。
J Clin Oncol. 2009 Feb 10;27(5):740-5. doi: 10.1200/JCO.2008.16.3055. Epub 2008 Dec 29.
3
Experience with irinotecan for the treatment of malignant glioma.伊立替康治疗恶性胶质瘤的经验。
Neuro Oncol. 2009 Feb;11(1):80-91. doi: 10.1215/15228517-2008-075. Epub 2008 Sep 10.
4
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.伊立替康（CPT-11）用于复发性恶性胶质瘤患者的2期试验：一项北美脑肿瘤联盟研究。
Neuro Oncol. 2006 Apr;8(2):189-93. doi: 10.1215/15228517-2005-010. Epub 2006 Mar 13.
5
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.成人复发性恶性胶质瘤患者每周使用伊立替康的2期研究：NABTT 97-11的最终报告
Neuro Oncol. 2004 Jan;6(1):21-7. doi: 10.1215/s1152851703000218.
6
Irinotecan therapy in adults with recurrent or progressive malignant glioma.伊立替康治疗复发性或进展性恶性胶质瘤成人患者。
J Clin Oncol. 1999 May;17(5):1516-25. doi: 10.1200/JCO.1999.17.5.1516.
Zotero 插件